Zacks Research Issues Positive Estimate for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities research analysts at Zacks Research increased their Q2 2025 earnings estimates for BioMarin Pharmaceutical in a note issued to investors on Wednesday, January 8th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $0.69 for the quarter, up from their previous forecast of $0.68. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.49 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q4 2026 earnings at $0.94 EPS and FY2026 earnings at $3.43 EPS.

Several other brokerages also recently weighed in on BMRN. Sanford C. Bernstein reduced their target price on shares of BioMarin Pharmaceutical from $116.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 17th. Evercore ISI reduced their price objective on shares of BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Scotiabank dropped their target price on BioMarin Pharmaceutical from $95.00 to $78.00 and set a “sector perform” rating for the company in a research report on Tuesday, September 17th. JPMorgan Chase & Co. reduced their price target on BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating on the stock in a report on Wednesday, October 30th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $80.00 price objective on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $94.20.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN opened at $67.38 on Monday. The company has a market cap of $12.84 billion, a P/E ratio of 40.35, a P/E/G ratio of 0.65 and a beta of 0.29. The business’s 50 day moving average price is $65.83 and its 200-day moving average price is $74.96. BioMarin Pharmaceutical has a fifty-two week low of $61.15 and a fifty-two week high of $96.64. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The company had revenue of $746.00 million during the quarter, compared to analysts’ expectations of $703.37 million. During the same quarter in the prior year, the business posted $0.26 EPS. The company’s revenue was up 28.4% on a year-over-year basis.

Insider Activity

In other news, EVP Charles Greg Guyer sold 5,278 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the sale, the executive vice president now owns 68,909 shares in the company, valued at approximately $4,573,490.33. This represents a 7.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.85% of the company’s stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMRN. nVerses Capital LLC acquired a new stake in shares of BioMarin Pharmaceutical during the third quarter worth $28,000. BOKF NA purchased a new position in BioMarin Pharmaceutical in the 2nd quarter worth $31,000. TD Private Client Wealth LLC lifted its position in BioMarin Pharmaceutical by 57.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 186 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in BioMarin Pharmaceutical during the 2nd quarter valued at about $47,000. Finally, Meeder Asset Management Inc. increased its holdings in shares of BioMarin Pharmaceutical by 920.8% in the third quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 663 shares during the period. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.